Model informed drug development has potentially a great deal to offer for vaccine development and in particular in seeking methods to extrapolate effectiveness. The definition of correlates of protection is critical for the development of next generation SARS-CoV-2 vaccine platforms. The complete chains of causality and interrelationships between vaccination, immune responses, protection and clinical endpoints are likely to be considerably complex. In this work, we propose a model-based approach for identifying mechanistic correlates of protection against disease acquisition based on mathematical modeling of viral dynamics and data mining of immunological markers. We apply the method to three different studies in non-human primates evaluating SARS-CoV-2 vaccines based on CD40-targeting, two-component spike nanoparticle and mRNA 1273. Inhibition of RBD binding to ACE2 appears to be a robust mechanistic correlate of protection across the three vaccine platforms although not capturing the whole biological vaccine effect. https://wcp2023.org/events/pharmacometric-model-informed-drug-development-in-infectious-diseases/